Estro Harmony from Xymogen

1. Cooling the Fire of Hormone
Imbalance
XYMOGEN Introduces:

2. Disclaimer
• The information that follows represents
XYMOGEN’s choices for presentation of
studies, comments, and/or opinions.
• It is assumed that the practitioner will
investigate the topic further and not use
this presentation as a sole source of
information from which to derive an
individualized patient protocol.

3. Time and Money
Relief for hot flushes, a predominant symptom of
menopause is among the most common reasons for
clinical visits of mid-life women and a major cost in health
care expenditures. The median duration of moderate to
severe hot flushes was 10.2 years…The most common
ages at onset of moderate-to-severe hot flushes were 45–
49 years

4. Hot flushes are associated with:
• poor sleep
• depressed mood
• decreased quality of life
• may worsen depressive symptoms
• signal the onset or relapse of a major depressive episode
• possibly mark underlying vascular changes that are associated
with subclinical cardiovascular disease
• greater incident coronary heart disease, may be a risk factor for
poor bone health.
• Obstet Gynecol. 2011 May;117(5):1095-104. doi:
10.1097/AOG.0b013e318214f0de.

5. 8-PN effects on Skin
Temperature
Treatment
Started
Treatment Ended

6. Menopausal Women
Benefit from 8-PN
phytoestrogen preparations containing this
standardized hop extract (8 PN at 100 mcg/day) may
provide an interesting alternative to women seeking
relief of mild vasomotor symptoms.

7. Small Dose that is
Fast and Effective
Heyerick A, Vervarcke S, Depypere H, Bracke M, De KD. A first
prospective, randomized, double-blind, placebo-controlled study on the use of a
standardized hop extract to alleviate menopausal discomforts. Maturitas. 2006 May
20;54(2):164-75.

8. Starts changing the
balance after one dose
Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin
after single oral doses to postmenopausal women.
Rad M, Hümpel M, Schaefer O, Schoemaker RC, Schleuning WD, Cohen AF, Burggraaf J.
Source
Centre for Human Drug Research, Leiden, The Netherlands.
Abstract
AIMS:
Pre-clinical data suggest that the racemic phyto-oestrogen 8-prenylnaringenin (8-PN) may have beneficial effects in
postmenopausal women
CONCLUSION: and may become an alternative to classical hormone replacement therapy (HRT) treatment
regimes. The aim of this study was to investigate the pharmacokinetics, endocrine effects and tolerability of chemically
• synthesized 8-PN indoses of up women. mg 8-PN were well tolerated by postmenopausal
Single oral postmenopausal to 750
women.
METHODS:
• The studypharmacokineticrandomized, double-blind, placebo-controlled, dose-escalation design with three
The was performed using a profile of 8-PN was characterized by rapid and probably
groups of eight healthy postmenopausal women. In each group six subjects received 8-PN and two subjects placebo.
complete enteral absorption, high metabolic stability, pronounced enterohepatic
8-PN was given orally in doses of 50, 250 or 750 mg. Drug concentrations in serum, urine and faeces were measured
up recirculation and tight dose linearity.
to 48 h and follicle-stimulating hormone/luteinizing hormone (LH) concentrations up to 24 h.
• The decrease in LH serum concentrations found after the highest dose
RESULTS:
All demonstrates the ability of 8-PN to exert systemic endocrine effects in
treatments were well tolerated and associated with a low incidence of (drug unrelated) adverse events. Serum
concentrations of free 8-PN showed rapid drug absorption and secondary peaks suggestive of marked enterohepatic
postmenopausal women.
recirculation. Independent of the treatment group, approximately 30% of the dose was recovered in excreta as free
compound or conjugates over the 48-h observation period. The first C(max) and AUC(0-48 h) showed dose linearity
with ratios of 1 : 4.5 : 13.6 (C(max)) and 1 : 5.2 : 17.1 (AUC). The750- mg dose decreased LH concentrations by 16.7%
(95% confidence interval 0.5, 30.2).
CONCLUSION:

9. Don’t confuse 8-PN with
other Hops Extracts
• Dr. Arne Heyerick is from the Integrated Multidisciplinary Center for
Molecular Nutrition Laboratory of Pharmacognosy and Phytochemistry
Faculty of Pharmaceutical Sciences
Ghent University – Ugent
• ”The mode-of-action and target applications for 8-PN vs reduced Iso-alphaacids (RIAA) are completely different. RIAA are anti-inflammatory
compounds and would work via inhibition of specific kinases in
inflammatory pathways. RIAA do not have any effect on estrogen-related
targets.”
• “8-PN is a phytoestrogen and interacts with estrogen-related targets to
modulate estrogen-related pathways. 8-PN can exert both pro-estrogenic
effects (eg. through estrogen receptor alpha and beta) and anti-estrogenic
effects (eg. through aromatase) and therefore acts as an estrogen
modulator rather than a pure estrogen such as estradiol.”

10. Hot flushes are associated with:
• poor sleep
• depressed mood
• decreased quality of life
• may worsen depressive symptoms
• signal the onset or relapse of a major depressive episode
• possibly mark underlying vascular changes that are associated with
subclinical cardiovascular disease
• greater incidence of coronary heart disease
• may be a risk factor for poor bone health.
• Obstet Gynecol. 2011 May;117(5):1095-104. doi: 10.1097/AOG.0b013e318214f0de.

11. 8-PN on CVD Progression
“8-PN exerted anti-aggregatory and antiadhesive effects on human platelets…”
“8-PN may represent a useful tool in the
therapy and prevention of vascular diseases
associated with platelet aggregation, such as
atherosclerosis, myocardial infarction,
coronary artery disease, and thrombosis.”

12. 8-PN and Breast Health
“These data suggest that hops extracts
possess cancer chemopreventive activity
through attenuation of estrogen metabolism
mediated by 8-PN.”
Cancer Prevention Research (Philadelphia, Pa.) [Cancer Prev Res (Phila)]
2012 Jan; Vol. 5 (1), pp. 73-81. Date of Electronic Publication: 2011 Oct 13.

13. 8-PN in Bone Health
“Bone properties with 8-PN supplementation reached a level
similar to that seen after estrogen supplementation.”
“Estrogen and 8-PN showed superior results in the analysis of
bone mineral density compared to calcium...”
“Treatment with 8-PN resulted in very good biomechanical
properties and showed an increased Bone Mineral Density
(BMD).”

14. Flax for Hot Flashes
• In an open-label, pilot study, flaxseed (40 grams/day) was
found to decrease mean hot flash scores after 6 weeks of
ingestion in women with moderate to severe menopausal
symptoms.
• 57% reduction in hot flashes but 50% of women
experienced GI symptoms and 6 (21%) withdrew from the
study.
• J Society Integrative Med 2007;5:106-12.
Graphic: http://www.linnea-worldwide.com/downloadsarticles/hmrlignan.pdf

15. Less is MORE with
HMRlignan
Hot Flashes Changes:
Start: 4.5 per day
Week 4: 2.7 per day (-37.2%)
Week 8: 2.0 per day (53.5%)
80 times more Flax for
similar results on hot flashes
40 grams
0.5 grams
8-week controlled study in 20
menopausal women (age 50-75 years.)
Presented at Scripps Integrative Medicine 5th Annual
Natural Supplements Conference, January 2008

16. Plant lignans create far reaching benefits after they have been
ingested and converted by intestinal bacteria to mammalian lignans.
OH
SecoisoLariciresinol
O
Enterodiol
OH
HO
Gut
microflora
(FLAX)
O
OH
O
O
Matairesinol
O
HO
O
OH
Gut
microflora
Hydroxymatairesinol (HMR)
O
• In humans, 7-HMR is a
direct metabolic precursorO
H
of the mammalian
lignan, enterolactone
(ENL).
Enterolactone
O
O
O
HO
O
HO
O
OH
OH

17. Vegetarians have high
Enterolactone Levels
Small doses
HMRLignans
significantly increase
enterolactone levels
in humans.*
http://www.linneaworldwide.com/downloadsarticles/hmr
lignan.pdf
This information has not been evaluated by the Food and Drug
Administration. This formula is not intended to diagnose, treat,
cure, or prevent any disease.

18. In humans, HMR Lignan is a direct metabolic
precursor of the mammalian
lignan, enterolactone (ENL).
Study type
Group, N
Result
Reference
Casecontrol
BC diagnosed
Pre-mp =68
Post-mp =126
Controls = 208
Serum ENL significantly
inversely correlated with BC
risk in both pre- and postmenopausal women
Pietinen et al.,
Cancer Epidemiol
Biom Prev
2001;10:339-44.
Casecontrol
BC diagnosed
Pre-mp = 220
Controls = 237
Piller, et al., Eur J
Premenopausal BC risk
Cancer Prevent
decreased with increasing
2006;15:225-32.
plasma ENL but not genistein.
Cohort
study
Palpable cysts,
n= 258
A direct correlation between
serum and cyst fluid ENL.
Inverse correlation between
cyst fluid ENL and EGF.
Boccardo et al.,
Breast Cancer Res
Treat 2003;79:1723.
Cohort
study
381 cases
381 controls
ER negative cancer,
protection at over 20 nmol/L
ENL
Olsen et al.,
Cancer Epidem
Biom Prev
2004;13:2084-9.

19. Enterolactone Benefits
for CVD
•Serum enterolactone (ENL) has been shown to
decrease Plasma F2-isoprostane (a measure of lipid
peroxidation)
•
Atherosclerosis 2002;160:465–9.
•Serum enterolactone (ENL) levels are inversely
correlated with risk of coronary heart disease-related and
cardiovascular-disease-related mortality.
•
Arch Intern Med 2003;163:1099–1104.

20. We have reviewed scientific evidence that appears to
demonstrate that lignans and 8-PN are important for healthy
hormone balance. We have mentioned cancer, cardiovascular
diseases, and anti-inflammatory activity.
•It’s important to remember that dietary
supplements CANNOT mitigate diseases or
replace drugs.
•
However, XYMOGEN products CAN
give your patients their best chance to stay
healthier longer*

21. Estro Harmony™
*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

22. Menopause Symptom Scores
decreased in 4 weeks with
Estro Harmony†
Case Studies by
David Haase, MD
†Case studies represent results of a single participant. Consumers should weigh these results with
other scientific data and should not expect the same results as those found in case studies alone.

23. Estro Harmony ensures that the standardized amount of 8 PN and
HMR Lignan are at clinically validated levels for optimal results.
Most hops formulations cannot make this same statement.

24. Clinical Applications
• Helps Protect Breast Cells*
• Relieves Normal Menopausal Symptoms*
• Hot Flashes*
• Supports Healthy Cardiovascular Status*
• Supports Bone Remodeling*
• Supports the Body’s Natural Process of Healthy
• Aromatase Activity*
*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.